Johnson & Johnson (JNJ)
Key Takeaways:
Company Overview
Johnson & Johnson is a global healthcare conglomerate with two core businesses: Innovative Medicine and MedTech. It develops, manufactures, and sells prescription medicines across oncology, immunology, neuroscience, pulmonary hypertension, infectious disease, and cardiovascular/metabolism, while its device franchise spans surgery, orthopaedics, cardiovascular, and vision. The company operates in virtually every country, relies on a large R&D engine, and has a long record of dividend growth. In 2025, sales were broad-based, led by strong oncology and cardiovascular growth, while immunology was dragged down by STELARA biosimilar erosion and MedTech faced tariff, China procurement, and restructuring pressures. J&J’s portfolio is benefiting from new launches and acquisitions such as CAPLYTA and Shockwave, but it also faces meaningful patent cliffs, heavy regulation, pricing controls, litigation overhangs, and a higher debt load after acquisition spending. The pending Orthopaedics separation suggests continued portfolio reshaping rather than a stable status quo.
Business Segments
Economic Moat Analysis
Johnson & Johnson deserves a wide moat classification because it combines unmatched healthcare scale, durable brand trust, deep regulatory experience, and broad diversification across drugs and devices. However, the moat is not impregnable: patent cliffs, biosimilar erosion, price regulation, and litigation materially weaken its protection around several major franchises. The result is a strong but imperfect moat—resilient at the enterprise level, yet vulnerable at the product level whenever exclusivity ends or policy changes shift reimbursement economics. The overall score reflects this balance: exceptional corporate durability, but less pricing power and less exclusivity durability than a truly fortress-like healthcare monopoly.
The company’s global reputation, physician familiarity, and long-standing credibility in healthcare support premium positioning and customer retention.
Massive global R&D, manufacturing, regulatory, and commercial scale creates cost, distribution, and development advantages that smaller rivals struggle to match.
Decades of operating under intense healthcare regulation create a meaningful capability advantage in approvals, compliance, and post-market execution.
In several device and specialty-medicine settings, clinical workflows, hospital contracts, and physician habits create friction against switching, though this is not absolute.
Patents and exclusivity still protect key products, but this moat is uneven and repeatedly tested by biosimilars, generics, and legal challenges.
A broad and active pipeline helps renew the franchise, though development risk remains high and many candidates will not succeed commercially.
Exposure across pharmaceuticals and medtech, plus multiple therapeutic areas, reduces the risk that one market or product failure fully undermines earnings.
Key Strengths
- Diversified Portfolio: The company has two large operating segments with multiple therapeutic and device franchises, reducing dependence on any single product or end market.
- Scale Advantage: Global reach, a broad manufacturing base, and deep commercial infrastructure provide resilience and bargaining power across healthcare channels.
- R&D Engine: The company invested $14.7 billion in R&D in 2025 and continues to replenish the pipeline with new products and label expansions.
- Cash Generation: Operating cash flow of $24.5 billion supports dividends, acquisitions, debt service, and ongoing investment despite litigation and restructuring costs.
- Dividend Record: The company raised its dividend for the 63rd consecutive year, reinforcing income-investor appeal and signaling durable cash flow.
- Oncology Momentum: DARZALEX, CARVYKTI, ERLEADA, and newer bispecifics are driving strong oncology growth and partially offsetting mature-product erosion.
- MedTech Breadth: Cardiovascular, surgery, and vision businesses provide non-pharma growth avenues and reduce pure drug-exclusivity dependence.
- Balance Sheet Access: Investment-grade ratings, substantial committed credit facilities, and access to commercial paper support liquidity flexibility.
Identified Weaknesses
- Patent Dependence: A meaningful share of revenue still relies on a relatively small number of biologic and specialty-drug products with finite exclusivity.
- STELARA Erosion: Biosimilar competition is already materially reducing one of the company’s largest products and will continue to pressure segment growth.
- Litigation Burden: Talc, opioid-related, shareholder, and other legal matters create recurring cash, earnings, and reputational uncertainty.
- Rising Leverage: Debt increased materially after acquisition funding, leaving a less conservative balance sheet than in prior periods.
- Price Pressure: IRA negotiation, Part D redesign, 340B dynamics, PBM pressure, and global reimbursement controls reduce pricing power.
- MedTech Cyclicality: Procedure volumes, hospital purchasing cycles, China VBP, and tariff exposure make device growth uneven and policy-sensitive.
- Integration Risk: Recent acquisitions increase execution risk, including commercial integration, R&D prioritization, and potential dilution of returns.
- Manufacturing Complexity: A global, highly regulated supply chain increases exposure to quality issues, interruptions, and compliance costs.
Growth Opportunities
- Pipeline Conversion: Multiple pending filings and approvals across oncology, immunology, and neuroscience could offset mature-product declines if launches succeed.
- CAPLYTA Expansion: The Intra-Cellular acquisition adds a meaningful neuroscience growth asset with room for broader adoption.
- TREMFYA Growth: TREMFYA is scaling well and has additional indications that could extend its life cycle and reduce reliance on legacy immunology assets.
- Cardiovascular Upside: Shockwave, Abiomed, and electrophysiology offer sustained growth potential in structurally attractive interventional markets.
- Orthopaedics Separation: A potential spin or separation could sharpen management focus and improve portfolio transparency, though execution risk is high.
- International Expansion: Emerging and developed markets still provide room for penetration, especially where healthcare access and procedure adoption remain underdeveloped.
- Lifecycle Management: Many core products have active line extensions, new indications, and device upgrades that can extend commercial life.
- Operational Simplification: Restructuring and portfolio pruning could improve margins if management executes without damaging revenue capacity.
Risk Factors
- Biosimilar Wave: STELARA and other mature biologics face continuing biosimilar entry, which can quickly compress revenue and margins.
- IRA Regulation: Government price negotiation and redesign of Medicare benefits can materially impair future U.S. pharmaceutical economics.
- Product Liability: Talc and other litigation could produce additional charges, settlement demands, or adverse judgments beyond current reserves.
- China and Trade Risk: Volume-based procurement, tariffs, export controls, and geopolitical friction can pressure both MedTech and pharma supply chains.
- Regulatory Tightening: FDA, EU, privacy, cybersecurity, AI, and data-localization rules are becoming more complex and expensive to satisfy.
- Patent Challenges: Generic and biosimilar challenges can erode exclusivity unexpectedly, especially for high-value therapies.
- Competitive Innovation: Rivals in oncology, immunology, and medtech continue to innovate aggressively, threatening share gains and pricing.
- Execution Risk: The planned Orthopaedics separation, acquisition integration, and restructuring programs could create operational distraction and one-time costs.
Valuation Metrics
P/E is 30.68 (Forward P/E 21.05): the market is pricing JNJ at a premium vs typical value targets, but the forward multiple improvement suggests expected earnings normalization/reacceleration.
PEG is 2.14, indicating valuation is somewhat high relative to its growth rate assumptions (growth doesn’t fully “justify” the current P/E).
Price/Sales (P/S) is 6.51 and Enterprise Value/Sales (EV/Sales) is 8.63—both are elevated, consistent with a quality/defensive premium rather than deep value.
P/B is 7.50, which is high; JNJ’s profitability is likely strong versus equity base, but book-value-based entry for value investors is not obviously cheap.
P/FCF is 28.68 and EV/EBITDA is 30.73: cash-flow and earnings power are valued richly; this typically requires either sustained margins or earnings growth to deliver returns.
Cash/sh is 0.81 vs Book/sh 8.61: the balance-sheet cash cushion exists but is not large enough to offset the premium valuation by itself.
Earnings & Profitability
TTM net income (Income) is 21.04B on Sales of 97.94B: Profit Margin is 9.70%—solid for a mega-cap healthcare company.
ROA is 0.12% (very low) and ROE is 9.84%: ROE is reasonable, but ROA being tiny suggests high asset base or accounting structure; ROIC is 10.67%, which is stronger and closer to economic profitability expectations.
Gross Margin is 68.03% and Operating Margin is 25.74%: strong operating profitability supports the idea that JNJ converts sales into earnings efficiently.
Earnings surprise/quality: EPS/Sales Surpr. is 9.73%—a positive surprise metric implies recent beats vs expectations (supports fundamentals despite high valuation).
EPS growth signals: EPS (ttm) 8.27? (given as 8.63) vs EPS next Y 12.58 and EPS this Y 9.84; EPS next 5Y is 10.67% with EPS past 3/5Y shown around 17.88%/14.90% (data suggests prior strength and expectation of continued improvement but possibly moderating).
Year-over-year: EPS Y/Y TTM is 2.78% and Sales Y/Y TTM is 6.27%—top-line is growing faster than EPS recently, so margin/expense discipline will be key for value delivery.
Growth Analysis
Analyst growth expectations are mixed-but-improving: EPS next Y is 12.58 and EPS next Q is 2.78, while EPS past 3/5Y rates (17.88%/14.90%) suggest the business has historically grown faster than the current TTM EPS pace.
Sales Y/Y TTM is 6.27% while EPS Y/Y TTM is 2.78%: growth is more sales-driven than earnings-driven in the most recent period—watch for operating leverage to translate sales into earnings.
EPS next 5Y is 10.67%: for a mature mega-cap, ~mid-teens to low-teens earnings growth expectation is supportive, but given PEG 2.14, the market may already be pricing a meaningful portion of that.
Quarterly momentum: EPS Q/Q is -7.21% and Sales Q/Q is 8.07%—near-term earnings softness with revenue strength. This pattern can resolve positively if costs normalize.
Financial Health
Quick Ratio is 0.09 and Current Ratio is 0.58: liquidity metrics look weak (especially quick ratio), suggesting reliance on cash generation and working-capital management rather than liquid assets.
Debt/Equity is 0.44 and LT Debt/Equity is 0.58: leverage is moderate, not extreme for a defensive healthcare compounder.
Option/Short (0.12%) is negligible; short-related risk appears not structurally overwhelming based on this figure.
Book/sh is 8.61 with Cash/sh 0.81: the balance sheet has accounting equity, but cash is not disproportionately high—so investors should rely on earnings/cash flow rather than liquid balance-sheet coverage.
Ownership Structure
Insider ownership is 8.63% with Insider transactions marked Yes/Yes: insider alignment is a positive quality signal (though it doesn’t guarantee near-term upside).
Institutional ownership is 77.19%: strong institutional backing typical of large, liquid quality equities.
Institutional transactions are 0.99% (positive sign): suggests institutions are not broadly distributing based on the provided metric.
Market Performance
52W range is 264.74–283.52 and Price is 267.57: the stock is near the lower end of its 52-week range, which can improve forward-looking entry for both styles.
Beta is 0.20 and volatility is 0.91 (with ATR 21.19?): JNJ is lower-volatility/defensive vs the market—useful for risk-managed compounding.
Relative volume is 1.89 (above average activity); could indicate information flow or positioning, but directionally it must be confirmed by trend.
Performance: Perf Week -1.65%, Month -0.42%, Quarter -0.48%, YTD 8.30%, and 3Y/5Y are very strong (Perf 3Y +42.78%, 5Y +69.98%, 10Y +124.11%).
Current valuation premium is consistent with strong long-term market recognition; near-term drawdowns do not necessarily imply fundamental deterioration.
Momentum & Volatility
RSI (14) is 43.54: below-neutral momentum (not oversold), suggesting the stock may still be digesting recent weakness.
SMA20 is 264.74, SMA50 is 267.57, SMA200 is 264.74 with Price 267.57: price is around/near key moving averages—technically not stretched, which supports a value/growth entry case if fundamentals hold.
Short float is 0.20% and Short interest is 6,343,718: short positioning exists but not unusually high; downside may be less driven by crowded short squeezes.
Relatively low beta (0.20) plus moderate ATR implies limited volatility—good for long-duration compounding, but may also mean upside during market rallies can be steadier rather than explosive.
Investment Recommendations
value Investor:
At/near the lower band of current trading and around major support: ~$265–$268 (near SMA200/SMA20 and close to the 52W low region). This is consistent with a “premium business, not a deep bargain,” so value entry should be anchored to support rather than a large discount to intrinsic value.
growth Investor:
For growth risk-adjusted entry, consider ~$268–$272. It captures current weakness while still allowing for rerating if EPS next Y moves toward 12.58 and margins stabilize.
Investment Summary
JNJ shows quality profitability (68% gross, 25.7% operating, 9.7% net) and reasonable leverage (Debt/Equity 0.44), with EPS next Y rising to 12.58 and EPS/5Y growth ~10.67%. However valuation is rich (P/E 30.7, P/FCF 28.7, EV/EBITDA 30.7; PEG 2.14). Value investors: buy on weakness near ~$265–$268. Growth investors: ~$268–$272 if earnings growth and margins reaccelerate. Defensive momentum: RSI 43 and near SMAs; long-term performance strong.